News

NeuraLight Presents Results on Parkinson’s Progression at IAPRD 2025

NeuraLight launches the PARATROOPER trial to advance the understanding of Oculometric Biomarkers in Parkinsonian Disorders

NeuraLight presents at the International Parkinson and Movement Disorder Society (MDS) Congress 2024

NeuraLight recognized among World’s Best Digital Health Companies in 2024

PALOMA Study Launches to Explore Oculometric Biomarkers in Parkinson’s Disease

NeuraLight presents at the International Parkinson and Movement Disorder Society (MDS) Congress 2023

A longitudinal trial launched to evaluate change over time in oculometric Biomarkers in Parkinson’s Disease

NeuraLight Wins SXSW Innovation Award in Health and MedTech

NeuraLight Joins the RADIEMS cohort longitudinal Study at Mount Sinai Multiple Sclerosis center

Prospective cross-sectional trial is launched to evaluate oculometric meausres in Parkinson’s Disease

NeuraLight and NeuroSense Partner to Use Novel  Biomarkers for ALS Drug Development